Regeneron envisions new dosing for Eylea’s label and it’s the moment of truth for BioMarin’s gene therapy for hemophilia A. For that and more, see inside.
FDA Action Alert: Regeneron, BioMarin, Eton and Amneal Read More »
CMS has stated that it will cover new Alzheimer’s drugs if the therapies are fully approved. But significant financial questions remain.
Opinion: Cracking the Code—Solving the Economic Puzzle of Leqembi Read More »
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced plans to advance its investigational drug LX9211 into late-stage development in a clinical program directed towards an application for regulatory approval in diabetic peripheral neuropathic pain, or DPNP.
Lexicon Announces Planned Advancement of LX9211 Into Late-Stage Development Read More »
Deal volumes declined 4% in the year ended May 15 compared to 2022, according to a PwC report. But the consulting firm is “optimistic” about the sector’s M&A outlook for the rest of the year.
Health services M&A holding steady despite economic headwinds Read More »
The voluntary plan would allow manufacturers to address evidence gaps through studies designed to answer specific questions.
CMS proposes pathway to earlier breakthrough device coverage Read More »
Shareholders are voting on whether to add investor Politan Capital’s picks to the board of the pulse oximeter maker, a move that could change the company’s direction.
Showdown at Masimo: Proxy battle targets CEO Kiani’s leadership, board Read More »
Sun Park’s background in healthcare and corporate finance, in addition to the long lead time between his appointment and start date as CFO, indicate Tenet’s efforts to ensure a smooth leadership changeover, according to analysts.
Tenet names ex-AmerisourceBergen executive as new CFO Read More »
Un biofármaco basado en un virus modificado genéticamente ha mostrado en pruebas de laboratorio una fuerte actividad antitumoral contra varios cánceres ginecológicos. En el camino por obtener un tratamiento que mejore las expectativas de vida de mujeres con disti …
Banking on its lead antibody APG777 for atopic dermatitis, Apogee Therapeutics is filing an initial public offering for an as-yet-undisclosed value.
Apogee Files for IPO with Promising Preclinical Immuno Asset Read More »
The FDA has again denied Intercept’s bid to have its obeticholic acid tablets approved in non-alcoholic steatohepatitis, forcing the company to abandon the indication and restructure operations.
FDA’s Second Rejection Ends Intercept’s NASH Aspirations Read More »
